Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 164

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 8
Chunk 164
---
 $463 $2,222 $(4)$2,226 $1.49 Non-GAAP adjustments:Amortization expense669 93 576 7 570 0.38 Goodwill and other intangible asset impairment charges46 8 37 — 37 0.02 Acquisition/divestiture-related net charges (credits)156 (1)157 — 157 0.10 Restructuring and restructuring-related net charges (credits)247 32 215 — 215 0.14 Investment portfolio net losses (gains) and impairments(0)0 (0)— (0)(0.00)EU MDR implementation costs34 5 29 — 29 0.02 Deferred tax expenses (benefits)— (139)139 — 139 0.09 Discrete tax items— (1)1 — 1 0.00 Adjusted$3,836 $461 $3,375 $3 $3,372 $2.26 

Nine Months Ended September 30, 2024(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$1,697 $413 $1,284 $(4)$1,288 $0.87 Non-GAAP adjustments:Amortization expense631 86 545 7 539 0.36 Goodwill and other intangible asset impairment charges276 33 243 — 243 0.16 Acquisition/divestiture-related net charges (credits)256 (59)315 — 315 0.21 Restructuring and restructuring-related net charges (credits)149 20 129 — 129 0.09 Investment portfolio net losses (gains) and impairments17 (0)17 — 17 0.01 EU MDR implementation costs39 5 34 — 34 0.02 Deferred tax expenses (benefits)— (120)120 — 120 0.08 Adjusted$3,065 $380 $2,685 $2 $2,